56. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Int Med 2015;175(4):608-615. 57. Michigan Opioid Prescribing Engagement Network. Opioid prescribing recommendations for surgery. 2019. https://opioidprescribing. info/ 58. Kim N, Matzon JL, Abboudi J, et al. A prospective evaluation of opioid utilization after upper-extremity surgical procedures: Identifying consumption patterns and determining prescribing guidelines. J Bone Joint Surg Am 2016;98(20):e89. 59. Chu J, Farmer B, Ginsburg B, et al. New York City emergency department discharge opioid prescribing guidelines. 2013. https://www1. nyc.gov/site/doh/providers/health-topics/opioid-prescribing-resources-for-emergency-departments.page 60. Thorson D, Biewen P, Bonte B, et al. Acute pain assessment and opioid prescribing protocol. Institute for Clinical Systems Improvement. 2014. https://www.icsi.org 61. VA/DoD Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guidelines for the management of opioid therapy for chronic pain. 2003. Contract number: V101 (93). 62. Food and Drug Administration. FDA approves first generic naloxone nasal spray to treat opioid overdose. FDA News Release. April 19, 2019. 63. Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: A systematic review. Ann Int Med 2017;167(3):181-191. 64. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: Evidence and recommendations for everyday practice. Mayo Clin Proc 2015;90(6):828-842. 65. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. 2019. https://www.fda.gov/Drugs/DrugSafety/ucm635038.htm 66. Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open 2023;6(8):e2327488. doi: 10.1001/jamanetworkopen.2023.27488 67. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. 68. Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants. 2017. www.fda.gov/Drugs/DrugSafety/ucm575307.htm 69. Binswanger IA, Glanz JM. Potential risk window for opioid overdose related to treatment with extended-release injectable naltrexone. Drug Saf 2018;41(10):979-980. 70. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatr 2015;23(2):63-75. 71. Walters SM, Liu W, Lamuda P, Huh J, Brewer R, Johnson O, Bluthenthal RN, Taylor B, Schneider JA. A national portrait of public attitudes toward opioid use in the US: a latent class analysis. Int J Environ Res Public Health 2023, Mar 2;20(5):4455. doi: 10.3390/ ijerph20054455. PMID: 36901465; PMCID: PMC10001548. 72. Food and Drug Administration. FDA approves first generic naloxone nasal spray to treat opioid overdose. FDA News Release. April 19, 2019. 73. Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addict 2012;107(9):1621-1629. 74. Schwartz RP. When added to opioid agonist treatment, psychosocial interventions do not further reduce the use of illicit opioids: a comment on Dugosh et al. J Addict Med 2016;10(4):283-285. 75. Substance Abuse and Mental Health Services Administration. Buprenorphine. 2019. https://www.samhsa.gov/medication-assisted- treatment/treatment/buprenorphine 76. Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis - buprenorphine myths and realities. N Engl J Med 2018;379(1):1-4. 77. Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend 2021 Apr 1;221:108627. doi: 10.1016/j.drugalcdep.2021.108627. Epub 2021 Feb 16. PMID: 33621805; PMCID: PMC8026666. 78. Dooley J, Gerber-Finn L, Antone I, Guilfoyle J, Blakelock B, Balfour-Boehm J, Hopman WM, Jumah N, Kelly L. Buprenorphine- naloxone use in pregnancy for treatment of opioid dependence: Retrospective cohort study of 30 patients. Can Fam Physician 2016 Apr;62(4):e194-200. PMCID: PMC4830675. 79. Metz VE, Brown QL, Martins SS, Palamar JJ. Characteristics of drug use among pregnant women in the United States: Opioid and non- opioid illegal drug use. Drug Alc Depend 2018;183:261-266.
Powered by FlippingBook